Published in J Virol on December 28, 2011
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology (2014) 1.34
What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med (2013) 1.27
Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis (2013) 1.23
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother (2013) 1.21
Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem (2012) 1.20
Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother (2014) 1.18
Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. Science (2017) 1.15
HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10
Novel therapeutic strategies targeting HIV integrase. BMC Med (2012) 1.06
Current perspectives on HIV-1 antiretroviral drug resistance. Viruses (2014) 1.04
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs. Mol Biol Int (2012) 1.03
Are subtype differences important in HIV drug resistance? Curr Opin Virol (2012) 0.99
Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses (2014) 0.96
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses (2015) 0.94
Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther (2015) 0.91
Crystal structure of the Rous sarcoma virus intasome. Nature (2016) 0.91
Will drug resistance against dolutegravir in initial therapy ever occur? Front Pharmacol (2015) 0.90
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One (2013) 0.89
Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol (2014) 0.88
Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol (2015) 0.87
Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother (2015) 0.86
Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol (2014) 0.85
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother (2014) 0.84
Retroviral Integrase Structure and DNA Recombination Mechanism. Microbiol Spectr (2015) 0.83
The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother (2014) 0.83
Integrase Strand Transfer Inhibitors in HIV Therapy. Infect Dis Ther (2013) 0.83
Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency. Viruses (2014) 0.83
HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol (2016) 0.82
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology (2015) 0.82
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother (2016) 0.82
Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother (2015) 0.82
A possible role for the asymmetric C-terminal domain dimer of Rous sarcoma virus integrase in viral DNA binding. PLoS One (2013) 0.82
Simian-tropic HIV as a model to study drug resistance against integrase inhibitors. Antimicrob Agents Chemother (2015) 0.81
Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. PLoS One (2015) 0.80
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother (2016) 0.78
Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology (2016) 0.78
Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl) (2013) 0.78
Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan. Sci Rep (2016) 0.77
Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J Antimicrob Chemother (2016) 0.77
HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS One (2014) 0.77
Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor. Antiviral Res (2014) 0.77
Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS. HIV AIDS (Auckl) (2014) 0.77
Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study. Acta Naturae (2015) 0.77
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Antimicrob Agents Chemother (2015) 0.77
Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. J Antimicrob Chemother (2015) 0.76
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo) (2012) 0.76
HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase. Antimicrob Agents Chemother (2014) 0.76
Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis (2014) 0.76
HIV-1 resistance to dolutegravir: update and new insights. J Virus Erad (2015) 0.75
Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase. Antimicrob Agents Chemother (2015) 0.75
Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight (2016) 0.75
Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data. Bioinformation (2016) 0.75
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. J Virol (2015) 0.75
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. MBio (2017) 0.75
Impact of HIV-1 Integrase L74F/V75I Mutations from a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. Antimicrob Agents Chemother (2017) 0.75
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One (2017) 0.75
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. MBio (2017) 0.75
HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity. J Virol (2017) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc (2010) 22.66
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Retroviral intasome assembly and inhibition of DNA strand transfer. Nature (2010) 4.99
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A (2000) 3.26
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr (2006) 3.24
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem (2008) 3.09
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother (2010) 2.89
Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother (2009) 2.76
The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature (2010) 2.58
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol (1998) 2.49
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Pre-calculated protein structure alignments at the RCSB PDB website. Bioinformatics (2010) 2.28
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol (2008) 2.27
Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A (2010) 2.16
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res (1994) 1.98
Development of antiretroviral drug resistance. N Engl J Med (2011) 1.88
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 1.83
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis (2011) 1.80
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS (2011) 1.62
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol (2009) 1.61
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol (2011) 1.58
Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog (2009) 1.53
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis (2010) 1.50
A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res (1994) 1.47
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
HIV-1 subtype distribution and the problem of drug resistance. AIDS (2004) 1.40
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS (2011) 1.38
Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol (2011) 1.36
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother (2011) 1.27
Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist Updat (2010) 1.22
Folding of the multidomain human immunodeficiency virus type-I integrase. Protein Sci (1994) 1.20
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
HIV transmission and primary drug resistance. AIDS Rev (2006) 1.12
Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother (2010) 1.08
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci (2011) 1.06
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS (2010) 1.03
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem (2009) 1.03
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol (2007) 1.03
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS (2011) 1.01
Defining the DNA substrate binding sites on HIV-1 integrase. J Mol Biol (2008) 1.01
Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 Is critical for HIV-1 infection. PLoS One (2009) 0.99
Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol (2009) 0.99
Fluorescent microplate-based analysis of protein-DNA interactions. I: Immobilized protein. Biotechniques (2003) 0.99
Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. Biochem J (2002) 0.95
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol (2011) 0.95
Identification of critical motifs within HIV-1 integrase required for importin α3 interaction and viral cDNA nuclear import. J Mol Biol (2011) 0.86
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res (2011) 0.83
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother (2010) 2.89
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother (2009) 2.76
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother (2006) 2.23
Whither or wither microbicides? Science (2008) 2.17
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (2003) 2.11
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother (2003) 2.04
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol (2005) 2.02
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol (2009) 2.00
Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol (2002) 1.96
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother (2003) 1.83
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother (2002) 1.82
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol (2008) 1.79
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS (2003) 1.78
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother (2011) 1.68
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A (2008) 1.64
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS (2011) 1.62
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res (2008) 1.61
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology (2004) 1.59
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol (2011) 1.58
RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol (2010) 1.55
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther (2003) 1.53
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr Opin Virol (2012) 1.40
The XVI International Conference on AIDS: the place to be! Retrovirology (2006) 1.39
Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res (2008) 1.36
Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS (2012) 1.35
Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology (2010) 1.34
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology (2014) 1.34
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. J Virol (2007) 1.31
The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr (2012) 1.30
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis (2009) 1.30
Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis (2006) 1.28
Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev (2008) 1.27
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic) (2003) 1.27
What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med (2013) 1.27
Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol (2002) 1.25
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS (2007) 1.24
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
The role of unintegrated DNA in HIV infection. Retrovirology (2011) 1.23
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology (2002) 1.22
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother (2013) 1.21
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol (2005) 1.21
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother (2007) 1.21
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS (2014) 1.19
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. Drugs (2008) 1.17
Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother (2009) 1.17
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis (2013) 1.13
Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA. J Virol (2003) 1.13
HIV transmission and primary drug resistance. AIDS Rev (2006) 1.12
Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother (2004) 1.12
Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. Eur J Immunol (2009) 1.12
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses (2003) 1.11
PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. Retrovirology (2006) 1.10
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 1.10
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev (2012) 1.10
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother (2007) 1.10
Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem (2013) 1.09